Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members see a lot more than you) LoginRegister
Psoriasis Club is a friendly on-line Forum where people with psoriasis or psoriatic arthritis
can get together and share information, get the latest news, or just chill out with others who understand. It is totally
self funded and we don't rely on drug manufacturers or donations. We are proactive against Spammers,
Trolls, And Cyberbulying and offer a safe friendly atmosphere for our members.
So Who Joins Psoriasis Club?
We have members who have had psoriasis for years and some that are newly diagnosed. Family and friends of those with psoriasis
are also made welcome. You will find some using prescribed treatments and some using the natural approach. There are people who
join but keep a low profile, there are people who just like to help others, and there are some who just like
to escape in the Off Topic Section.
Joining Couldn't Be Easier: If you are a genuine person who would like to meet others who understand,
just hit the Register button and follow the instructions.
Members get more boards and privileges that are not available to guests.
OK So What Is Psoriasis?
Psoriasis is a chronic, autoimmune disease that appears on the skin. It
occurs when the immune system sends out faulty signals that speed up the
growth cycle of skin cells. Psoriasis is not contagious. It commonly
causes red, scaly patches to appear on the skin, although some patients
have no dermatological symptoms. The scaly patches commonly caused by
psoriasis, called psoriatic plaques, are areas of inflammation and
excessive skin production. Skin rapidly accumulates at these sites which
gives it a silvery-white appearance. Plaques frequently occur on the
skin of the elbows and knees, but can affect any area including the
scalp, palms of hands and soles of feet, and genitals. In contrast to
eczema, psoriasis is more likely to be found on the outer side of the
joint.
The disorder is a chronic recurring condition that varies in severity
from minor localized patches to complete body coverage. Fingernails and
toenails are frequently affected (psoriatic nail dystrophy) and can be
seen as an isolated symptom. Psoriasis can also cause inflammation of
the joints, which is known as (psoriatic arthritis). Ten to fifteen
percent of people with psoriasis have psoriatic arthritis.
The cause of psoriasis is not fully understood, but it is believed to
have a genetic component and local psoriatic changes can be triggered by
an injury to the skin known as Koebner phenomenon. Various
environmental factors have been suggested as aggravating to psoriasis
including stress, withdrawal of systemic corticosteroid, excessive
alcohol consumption, and smoking but few have shown statistical
significance. There are many treatments available, but because of its
chronic recurrent nature psoriasis is a challenge to treat. You can find more information
Here!
Got It, So What's The Cure?
Wait Let me stop you there! I'm sorry but there is no cure. There are things that can help you
cope with it but for a cure, you will not find one.
You will always be looking for one, and that is part of the problem with psoriasis There are people who know you will be
desperate to find a cure, and they will tell you exactly what you want to hear in order to get your money. If there is a
cure then a genuine person who has ever suffered with psoriasis would give you the information for free. Most so called cures
are nothing more than a diet and lifestyle change or a very expensive moisturiser. Check out the threads in
Natural Treatments first and save your money.
Great so now what? It's not all bad news, come and join others at Psoriasis Club and talk about it. The best help is from accepting it and talking
with others who understand what you're going through. ask questions read through the threads on here and start claiming
your life back. You should also get yourself an appointment with a dermatologist who will help you find something that can
help you cope with it. What works for some may not work for others
Posted by: Fred - Sat-13-02-2016, 13:21 PM
- Replies (8)
This is a large population based cohort study that looked at the relation of chronic kidney disease in psoriasis patients.
Quote:Aim:
Using a population-based cohort, Wan et al. examined the risk of moderate-to-advanced (stage 3–5) chronic kidney disease (CKD) in patients with psoriasis.
Setting and design:
A population-based cohort was constructed using The Health Improvement Network (THIN) database. THIN is an electronic primary healthcare records database containing routinely collected medical diagnosis and drug prescribing data on > 9 million patients in the U.K. Data were collected prospectively on 143 883 adults (aged 18–90 years) with psoriasis. Of these, 7354 had severe psoriasis, as defined by prescription codes for systemic medication or treatment codes for phototherapy. Patients with psoriasis were matched with up to five nonpsoriasis age- and practice-matched controls. Patients with a diagnosis of CKD before study entry were excluded. In addition, baseline data from the Incident Health Outcomes and Psoriasis Events (iHOPE) study, a cohort of 8731 primary care patients aged 25–64 years with psoriasis, was included. Psoriasis severity was categorized according to body surface area (BSA) involvement as estimated by general practitioners. A similar method using a patient-reported BSA assessment tool was previously validated by the same group. Patients were matched by age and practice with 10 nonpsoriasis controls.
Study exposure:
Psoriasis, identified on the basis of a recorded diagnostic code for psoriasis.
Outcomes:
Incident CKD was defined as the presence of a recorded diagnostic code consistent with moderate-to-advanced (stage 3–5) CKD or laboratory parameters consistent with the diagnosis (estimated glomerular filtration rate < 60 mL min−1 1·73 m−2) during follow-up. Prevalent CKD (as defined above) in the cross-sectional data from the iHOPE study.
Results:
The adjusted hazard ratios for incident CKD were 1·05 [95% confidence interval (CI) 1·02–1·07], 0·99 (95% CI 0·97–1·02) and 1·93 (95% CI 1·79–2·08) in the overall, mild and severe psoriasis groups, respectively. In the nested cross-sectional study (iHOPE) the adjusted prevalence odds ratios for CKD were 0·89 (95% CI 0·72–1·10), 1·36 (95% CI 1·06–1·74) and 1·58 (95% CI 1·07–2·34) in the mild, moderate and severe psoriasis groups, respectively.
Conclusions:
Moderate-to-severe psoriasis is associated with an increased risk of moderate-to-advanced CKD, independently of traditional risk factors.
Posted by: Fred - Sat-13-02-2016, 13:10 PM
- Replies (1)
This small study looked at pediatric psoriasis and systemic therapies.
Quote:Background:
Psoriasis has an estimated prevalence of 0.5% to 2.0% in children. There is a paucity of data regarding the management and safety of treatments currently available for children with moderate to severe psoriasis. The aim of this study was to evaluate the treatment response and safety of systemic therapies used to manage moderate to severe pediatric psoriasis in a single referral center. Despite a small sample size, it was hypothesized that multiple therapeutics used for adult psoriasis would have a similar side-effect profile and positive disease response when used in a pediatric population.
Methods:
A retrospective case series evaluated 51 children with moderate to severe psoriasis treated with systemic therapies for adverse event occurrence and for disease response using a 5-point Physician Global Assessment scale.
Results:
Fifty-one patients, some of whom used multiple treatment options, produced 80 treatment data points. Adverse events were reported in 29 of these 80 treatments, with most being minor, subjective side effects. Overall, the most commonly reported side effect was fatigue, which was reported in 7.5% of treatments. Because of the small sample size, the data collected are limited and may not represent a comprehensive safety profile, nor do they allow comparison of efficacy between therapies. This case series found that biologic and immunomodulating therapies provide well-tolerated treatments with positive disease response for moderate to severe pediatric psoriasis.
Conclusion:
Although sample size and study design limit the data from this study, the study provides some guidance where little exists and helps to support the use of these treatments in this setting.
Posted by: Fred - Thu-11-02-2016, 21:02 PM
- Replies (8)
A bit of a biased study as it was funded by Novartis the makers but it suggests Coentyx (secukinumab) significantly improves patient-reported itching, pain, and scaling.
Methods:
ERASURE (n = 738) and FIXTURE (n = 1306) were double-blind, multicenter phase 3 studies in adults randomized to secukinumab (300, 150 mg, n = 1144) or placebo (n = 574) (administered at Weeks 0, 1, 2, 3, and 4, followed by dosing every 4 weeks) or a biologic active control (FIXTURE only). Patient-reported itching, pain, and scaling were assessed during the first 12 weeks of treatment using the PSD.
The results reported here are limited to subjects in the secukinumab and placebo treatment groups who completed the PSD. The proportions of subjects achieving prespecified responses (improvement:reduction of at least 2.2 points for itching, 2.2 points for pain, or 2.3 points for scaling) were compared for secukinumab versus placebo.
Results:
Overall, 39% of subjects completed the PSD at baseline and Week 12 (n = 453 secukinumab; 225 placebo). Subjects treated with secukinumab achieved significantly greater improvements in itching, pain, and scaling at Week 12 versus placebo (all P < 0.0001) and had significantly greater proportions of itching, pain, and scaling responders at Week 12 versus placebo (all P < 0.05).
Conclusion:
Secukinumab significantly improves patient-reported itching, pain, and scaling in adults with moderate to severe psoriasis compared with placebo.
Hi been on fumaderm for a year got a letter at xmas saying blood count is low and to lower dosage
Had bloods taken a few weeks ago and still low but my skins breaking out again and on my fave and hands bad
Do I up the dosage myself to 6 tabs a day as this seems to clear it as the letter for low blood count does not seem to be anything to worry about
I have loads of these tablets
Hi, i'm currently on fumaderm and it has almost cleared my psoriasis. However the psoriasis on my ankles is being stubbron and doesn't seem to be clearing. Also does the pigmintation leave ? I still have red skin colouring?
Is there a link between stopping Humira and headaches? I didn't do last weeks jab and I've had two migraines.. Could be just coincidence but I haven't had migraines for years.
Posted by: Fred - Fri-05-02-2016, 22:02 PM
- Replies (3)
This study looked at psoriatic arthritis patients using bio treatments and concluded the rate of infection was higher than of those with just psoriasis.
Quote:Objective:
To investigate the rate, type, characteristics, and predictors of infection in a cohort of patients with psoriatic arthritis (PsA) and a cohort of patients with psoriasis without arthritis (PsC).
Methods:
A cohort of patients with PsA and a cohort of patients with PsC were followed according to a standard protocol and information on the occurrence of infections was recorded. The rate of infection was estimated by fitting an exponential model. A Weibull regression model was fitted to estimate the relative risk of first infection associated with a number of covariates. Risk factors for recurrent infections were investigated using generalized estimating equations.
Results:
There were 498 and 74 infections reported among 695 and 509 patients with PsA and PsC, respectively, with an incidence rate of 19.6 per 100 person-years in the PsA cohort compared with 12.2 in the PsC cohort. The HR of the time to the first infection in PsA versus PsC was 1.6 (p = 0.002), and higher in patients treated with biologics versus nonbiologics at 1.56 (95% CI 1.22–2.00) in PsA and 1.50 (95% CI 0.64–3.54) in the PsC cohorts. Female sex and treatment with biologics were associated with infection in the PsA cohort, whereas a lower Psoriasis Area and Severity Index score and a higher Functional Comorbidity Index were associated with infection in the PsC cohort. Ultraviolet treatment was protective against infection in both cohorts. No difference in rates of hospitalization was found (p = 0.66). There were no infection-related deaths in either cohort.
Conclusion:
The incidence rate of infection was higher in the PsA than the PsC cohort and higher among patients treated with biologics. The data confirm the association between infection and biologic treatment in psoriatic disease.
Posted by: phil - Fri-05-02-2016, 13:56 PM
- Replies (6)
Went to Guys hospital yesterday and asked them for an update on Fumaderm.
Because of the slim chance off getting the Jc virus,which is untreatable,
they have stopped prescribing Fumaderm to any new patients
for the few that are still on them if there lymphocyte drops to 0.7
or lower ( like me ) they are taken off them for good. the ones that have normal
lymphocyte counts are now told if they want to stay on them they have to sign a consent form.
this only applies to Guys hospital.
Posted by: Fred - Thu-04-02-2016, 20:57 PM
- Replies (8)
This study suggests the older you get the less likely you are to get a Bio treatment for psoriasis.
Quote:Background:
Inequality in healthcare has been identified in many contexts. To the best of our knowledge, this is the first study investigating age inequality in the form of prescription patterns of biologics in psoriasis care.
Objectives:
To determine whether patients with psoriasis have equal opportunities to receive biological medications as they age. If patients did not receive equal treatment, a subsequent objective was to determine the magnitude of the disparity.
Methods:
A cohort of biologic-naive patients with psoriasis was analysed using Cox proportional hazards models to measure the impact of each additional year of life on the likelihood of initiating biological treatment, after controlling for sex, body mass index, comorbidities, disease activity and educational level. A supporting analysis used a nonparametric graphical method to study the proportion of patients initiating biological treatment as age increased, after controlling for the same covariates.
Results:
The Cox proportional hazards model resulted in hazard ratios of a 1-year increase in age of 0·96–0·97 depending on calendar-year stratification, which implies that an increase in age of 30 years corresponds to a reduced likelihood of initiating biological treatment by 61·3–67·6%. The estimated proportion of patients initiating biological medication always decreased as age increased, at a statistically significant level.
Conclusions:
Patients with psoriasis have fewer opportunities to access biological medications as they age. This result was shown to be applicable at all stages in a patient's life course and was not only restricted to the elderly, although it implies greater disparities as the age difference between patients increases. These results show that inequality in access to biological treatments due to age is prevalent in clinical practice today. Further research is needed to investigate the extent to which this result is influenced by patient preferences.
Source: onlinelibrary.wiley.com
Funded by:
Swedish Board of Health and Welfare
Swedish Association of Local Authorities and Regions
Västerbotten County Council
Posted by: Fred - Tue-02-02-2016, 21:01 PM
- No Replies
This small study looked at the levels of High mobility group box 1 protein (HMGB1) in patients with psoriasis. It showed an increased level of HMGB1 in patients with psoriasis and suggests that levels are significantly increased with disease progression and are down regulated after standard therapies.
Quote:Background:
Psoriasis vulgaris (PV) is an autoimmune-related chronic inflammatory disease, which appears mostly in skin, but also affects the vascular and metabolic system. The incidence of PV is 2–3% in the general population and there is still no possibility to cure. Trigger factors have been identified to initiate and maintain inflammation in the skin, which is characterized by Th1-, Th17- and Th22- cells.
Objective:
We hypothesize that the damage-associated molecular pattern (DAMP) molecule high mobility group box 1 (HMGB1) plays a role in the pathogenesis of PV. HMGB1 is a DNA-binding protein located in the nucleus, which acquires cytokine-like properties once released from the cell upon necrotic cell death or actively secreted by immune cells in inflammation and cancer.
Methods:
We recruited 90 psoriatic patients under and without therapy with mild, intermediate and severe progression of disease, defined by the Psoriasis Area Severity Index. Serum levels of HMGB1 in patients with PV were detected by enzyme-linked immunosorbent assay (ELISA).
Results:
Our results show an increased level of HMGB1 in the sera of patients with PV in comparison to healthy donors. Furthermore, our analyses reveal that HMGB1 levels are significantly increased with disease progression and are downregulated after standard therapies for PV have been conducted.
Conclusion:
Our data provide insights into a possible role of HMGB1 for inflammation in PV.
Hi, my name is Inge and I'm from Belgium. I have an 8 year old daughter Nore.
When she was 4 years old she had, after the separation from me and her father, a first time psoriasis. The dermatologist immediately asked if Nore had experienced something emotionally . We got all kinds of ointments prescribed with cortisone. Over the last 4 years she got some scabs on her head and face, not heavy till last december. It started with a spot here and there but during the holidays it got much heavier. Head, face, , back, sides, belly and legs. This is accompanied by severe itching this time. I don't want to use cortisone.
Does anyone here has a child that has psoriasis? Does anyone have some advice...again, I do not want to use cortisone. Thanks a lot for your help!
Hope I've posted this in the right place.I've suffered with psoriasis for the past 10 years and psoriatic arthritis for the last 7 years.I've managed to control the psoriasis for most of the 7 years due to injecting methotrexate then moving onto humira.Also taking other medication.For the last month ive been poorly with one thing or another and yesterday a trip to the doctors with me being covered head to toe in spots to be told its guttate psoriasis.apparently brought on by tonsillitis just wondered if anyone else has experienced this and why humira doesn't seem to have stopped it.
Hi all
Stumbled upon this forum at lunch time and you seem like a happy bunch, so thought I'd give it a go. Never done a forum before so please excuse if I drop the odd clanger. I've had P for about 13 years (I have always been a late starter). Sadly non of the topicals or UV have had any success. Sort of wrestling with the thought of hitting the 'hard' stuff now.
Back again on behalf of my 77 year old husband, desperate for help and to find out if anyone has had anything similar experience wise. Fumaderm started in July and built up to full dose - 2x monthly blood tests - took a while, but the psoriasis did subside. In October consultant found blood in urine and sent us to the GP who thought it was an infection. Saw consultant on 9th and again blood in the urine. He then said he would refer to a haematologist. I then got a letter yesterday saying my husband had been referred to the Nephrology Team and the Heamaturia Clinic - the figure from the Urinalysis PCR showed protein to creatine ratio 72 - I think it should be below 30? My husband also has anaemia and low sodium.
I was somewhat surprised to read that proteinuria is a very rare side affect of Fumaderm. The Dermo has asked the Clinic Consultant Nephrologist if my husband should continue to take the Fumaderm but has said to stay on it until he hears back. I am concerned because my husband also has Lupus which I think puts him at higher risk anyway of kidney problems yet I do not want him to come off the Fumaderm unless really necessary.
GP is also suggesting a bladder scan - he also did extra tests on Tuesday for something but laughingly said he would not tell me what he was testing for because I would only 'google it'. !!!! My husband is 77 and weighs less than 8st - lost 3st since the Summer so I do not honestly think I am being neurotic. These test results seem to suggest a potential kidney problem to me! Also the blood test end of December showed a borderline Urea result and that is the one the GP wanted re tested. I am struggling to try and work out how these medical people work together and who is responsible for what! I guess I just wait for the appointments to come through and take it from there? I cannot easily go with my husband although he is quite deaf, because the ambulance service won't take me and a taxi would be £70 return. I think I will phone when I get the appointments and ask exactly what is going on because if he does have kidney disease and advice is given on how to manage it, I think I may well need to be there with him. Sorry for rant - basically I know some of you have been on Fumaderm long term and wondered how common this is or could it even be totally unconnected and more likely due to the Lupus. On the bright side, maybe the consultant is just being cautious and if there is kidney disease it is very mild. Thanks for reading.
Hi guys.. If I haven't met you yet I'm Danny from England, I've had p for 16 years I'm about 60 percent covered and started aceterin 7 weeks ago,, 20 mg a day,, so far p is getting worse.. I was wandering if any of you have found that alcohol causes you to flare, I'm not sure, then again I do like a beer or two as I work in a brewery Look forward to hearing your feedback
You have to register before you can post on our site.
Members Images
Join Psoriasis Club
Psoriasis Club is self funded, we don't rely on sponsorship or donations. We offer a safe
friendly forum and are proactive against spammers, trolls, and cyberbullying. Join us here!
No Advertising.
No Corprate Sponsors.
No Requests for Donations.
No Cyber-Bullying.
No Scams or Cures.
No Recruitment Posts.
No promotions or offers.
No Trolls.
No Spam.
Just a small bunch of friendly people with psoriasis sharing information and support.
Forum Statistics
» Members: 987 » Latest member: paul1961 » Forum threads: 7,146 » Forum posts: 261,563
There are currently 54 online users. »1 Member(s) | 52 Guest(s) "YOYO" The Psoriasis Club Bot Is On-line, Fred
Psoriasis Cure!
How many people have Psoriasis?
In 2012 there were approximately 36.5 million prevalent cases of psoriasis, and by 2022, GlobalData epidemiologists forecast that this figure will reach approximately 40.93 million.
The condition affects individuals of both sexes and all ethnicities and ages, although there is a higher prevalence of psoriasis in the colder, northern regions of the world.
The prevalence of psoriasis in the central region of Italy is 2.8 times greater than the prevalence in southern Italy.
Caucasians have a higher prevalence of psoriasis compared with African-Americans, but African-Americans in the US tend to suffer from a more severe form of the disease.
